RedHill Biopharma (RDHL) Tops Q4 EPS Views
Tweet
Share
E-mailGet Alerts RDHL Hot Sheet
Join SI Premium – FREE
RedHill Biopharma (NASDAQ: RDHL) reported Q4 EPS of $0.06, $0.66 better than the analyst estimate of ($0.60).
EPS in Q413 was 0.05.
For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
- Rothschild Redburn Upgrades Apple (AAPL) to Buy
- International Petroleum Corporation Announces Results of Normal Course Issuer Bid
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
